Back to Search Start Over

Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses.

Authors :
McKee SJ
Young VL
Clow F
Hayman CM
Baird MA
Hermans IF
Young SL
Ward VK
Source :
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2012 May 10; Vol. 159 (3), pp. 338-45. Date of Electronic Publication: 2012 Feb 22.
Publication Year :
2012

Abstract

Virus-like particles (VLP) are effective vehicles for delivery of heterologous antigen to antigen-presenting cells. However VLP alone are insufficiently stimulatory to generate the signals required to facilitate effective priming of naïve T cells. We show that the VLP derived from rabbit hemorrhagic disease virus can bind the galactose-containing adjuvant α-galactosylceramide to form a composite particle for co-delivery of antigen and adjuvant to the same antigen-presenting cell. Vaccination with VLP and α-galactosylceramide activated splenic iNKT cells to produce IFN-γ and IL-4, led to the generation of antigen-specific T cells that protected prophylactically against subcutaneous tumor challenge, and was more effective at generating anti-tumor immune responses than either component individually. These data demonstrate a novel method for immunopotentiating VLP to increase their efficacy in the generation of anti-tumor responses via the innate ligand recognition properties of calicivirus-derived nanoparticles.<br /> (Copyright © 2012 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-4995
Volume :
159
Issue :
3
Database :
MEDLINE
Journal :
Journal of controlled release : official journal of the Controlled Release Society
Publication Type :
Academic Journal
Accession number :
22386518
Full Text :
https://doi.org/10.1016/j.jconrel.2012.02.015